Detalhe da pesquisa
1.
Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.
Cancer Immunol Immunother
; 66(2): 233-245, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27530271
2.
Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?
Cancer Immunol Immunother
; 65(4): 453-63, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26059279
3.
Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels.
Cytokine
; 61(3): 885-91, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23357299
4.
Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia.
Cancers (Basel)
; 12(8)2020 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32764229
5.
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
Cancers (Basel)
; 11(6)2019 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31234588
6.
Hepatitis B virus infection.
N Engl J Med
; 360(3): 304; author reply 305-6, 2009 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19144950
7.
In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients.
Front Immunol
; 8: 931, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28824651
8.
Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications.
Cytometry B Clin Cytom
; 92(5): 361-370, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27598686
9.
Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
Br J Haematol
; 136(2): 276-85, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17233819
10.
Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
Am J Hematol
; 80(4): 271-81, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16315252